Joshua Baker
Clinical Genetics (M.D.) · Chicago, ILNPI 1134534597
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 72.0% of it on its own, with 14 other manufacturers making up the rest.
Across 224 payments — averaging $986.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$159K
- Ultragenyx Pharmaceutical Inc.$35K
- Amgen$14K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Travere Therapeutics, Inc.$4K
- Zevra Therapeutics Inc$2K
- plus $4K from 9 others
Across 18 payments — averaging $12,182 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$157K
- Recordati_rare_diseases_inc.$52K
- Sanofi US Services Inc.$10K
What the payments were for
- Consulting fees$55,79825%
- Speaking & faculty fees$130,38459%
- Travel & lodging$28,65513%
- Food & beverage$6,1263%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 128 | $159,035 |
| Ultragenyx Pharmaceutical Inc. | 42 | $34,532 |
| Amgen(2 entities) | 24 | $14,484 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $4,186 |
| Travere Therapeutics, Inc. | 1 | $3,500 |
| Zevra Therapeutics Inc | 1 | $1,600 |
| Intrabio Inc | 1 | $1,560 |
| Eton Pharmaceuticals, Inc. | 3 | $1,050 |
| Biomarin Pharmaceutical Inc. | 6 | $499 |
| Immedica Pharma US, Inc. | 5 | $233 |
| PTC Therapeutics, Inc. | 2 | $139 |
| Eli Lilly | 1 | $118 |
| Chiesi USA, Inc. | 2 | $44 |
| Medunik USA Inc. | 1 | $26 |
| Amicus Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical genetics (m.d.) providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Betaine AnhydrousBetaine | 21 | $46,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eton Pharmaceuticals, Inc.Betaine Anhydrous | $1,050 | $46,35321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical genetics (m.d.) providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Chicago
- Barbara BurtonChicago$762K
- Carlos PradaChicago$303K
- Joel CharrowChicago$189K
- William DobynsChicago$2K
- Susan EchiverriChicago$2K
- Miguel BarajasChicago$1K
- Brandon ChalazanChicago$603
- Gifty BhatChicago$149
- Mindy LiChicago$49
- George HogansonChicago$30
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.